Syringobulbia in pediatric patients with Chiari malformation type I

Arnold H Menezes1,2, Jeremy D W Greenlee1,3, Brian J Dlouhy1,4

  • 11Department of Neurosurgery, University of Iowa Carver College of Medicine.

Insights

Syringobulbia (SB) in children with Chiari malformation type I (CM-I) is rare (4%), often presenting with headaches and cranial nerve issues. Posterior fossa decompression effectively treats SB and associated syringomyelia.

Area of Science:

  • Neurology
  • Neurosurgery
  • Pediatric Medicine

Background:

  • Syringobulbia (SB) is a rare condition, infrequently associated with Chiari malformation type I (CM-I) in pediatric patients.
  • Understanding the presentation, treatment, and outcomes of CM-I-associated SB is crucial for effective management.

Purpose of the Study:

  • To review pediatric cases of CM-I-associated SB managed at the institution.
  • To analyze the presentation, surgical treatment strategies, and outcomes of this rare condition.

Main Methods:

  • Analysis of a prospectively maintained institutional database of craniovertebral junction abnormalities (post-1984 MRI era).
  • Inclusion criteria: pediatric patients with CM-I and SB, excluding cases with tumors, infections, or CM-II.
  • Data collected: symptoms, physical and radiological findings, surgical approach, intraoperative details, and outcomes.

Main Results:

  • 13 (4%) of 326 pediatric CM-I patients had associated SB.
  • Headache, neck pain, and cranial nerve deficits (vagus, glossopharyngeal, trigeminal, abducens, hypoglossal) were common.
  • All patients had syringomyelia (SM); SB involved the medulla and, in some, the pons, midbrain, or cerebrum.
  • SB communicated with the fourth ventricle in 54% of cases.
  • Posterior fossa decompression with intradural exploration was performed on all patients.
  • Occlusion of the foramen of Magendie by an arachnoid veil was noted in 9 cases.
  • Cranial nerve palsies resolved in 11/13 patients, and SB improved in all 13.
  • SB improvement preceded SM improvement.

Conclusions:

  • The incidence of SB in surgically treated pediatric CM-I patients is 4%, invariably accompanied by SM.
  • SB commonly involves the medulla and frequently communicates with the fourth ventricle.
  • Posterior fossa decompression with intradural exploration and duraplasty is an effective treatment for pediatric CM-I-associated SB.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
277
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
310
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
73.0K
Types of Hormones02:13

Types of Hormones

Hormones can be classified into three main types based on their chemical structures: steroids, peptides, and amines. Their actions are mediated by the specific receptors they bind to on target cells.
84.1K